PTMs of tau proteins lead to structural and molecular diversity that may be linked to disease staging and contribute to AD clinical heterogeneity and disease progression (Arakhamia et al., 2020; Dujardin et al., 2020; Xia et al., 2021). Here, MAPT is linked to Alzheimer disease.